Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Quinonic derivatives active against Toxoplasma gondii

  • 73 Accesses

  • 5 Citations


Quinonic derivatives were tested against a virulent RH strain of Toxoplasma gondii maintained in cell culture in THP-1, a human myelomonocytic cell line. The derivatives were tested at various doses (0.5–4 µg/ml) and compared with the reference molecules clindamycine, sulfadiazine, pyrimethamine and atovaquone. The percentage of parasite growth inhibition was observed after 72 h of incubation. The tested derivatives are bicyclic, tricyclic or tetracyclic quinones. Eight of these compounds exhibit over 70% inhibition of parasite growth; and two were nearly equipotent to pyrimethamine. These data indicate that the most active compounds against the RH strain of T. gondii are bis-heterocyclic quinones.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Electronic Publication

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sarciron, M., Nebois, P., Pautet, F. et al. Quinonic derivatives active against Toxoplasma gondii . Parasitol Res 88, 969–971 (2002). https://doi.org/10.1007/s00436-002-0615-6

Download citation


  • Cell Culture
  • Growth Inhibition
  • Quinone
  • Active Compound
  • Tricyclic